Global Rheumatoid Arthritis Drugs Market is Estimated to Value Over USD 30 Billion by 2026 End

  • 17 Oct 2019

Global Rheumatoid Arthritis Drugs Market is estimated to value over USD 30 billion by 2026 end and register a CAGR of over 4.3% during the forecast period 2019 to 2026.

Rheumatoid arthritis majorly affects joints coupled with extra articular organs and articular tissues. The disease is quite often progressive and it results in stiffness, swelling and pain in joints. Over 2% of the world population is affected by rheumatoid arthritis. It mainly occurs during the middle ages, and women are more affected in comparison with men. As rheumatoid arthritis (RA) has no permanent cure, the primary treatment goals are to decrease inflammation, prevent bone deformity, improve a person’s overall body functionality and reduce pain. This may be achieved through the use of assistive devices and through exercise coupled with NSAIDs, pain medication and steroids that are frequently used to assist the symptoms. Disease-modifying antirheumatic drugs (DMARDs) can be used to slow down the progression of the disease. These drugs are the primary source of RA treatment and have been found useful in improving overall functional abilities, decreasing joint damage and improving symptoms.

However, early diagnosis and treatment are key for better disease management. Latest advancements in biosimilars can be used for treating RA and increasing approvals of these technologies by regulators have created new opportunities for expanding the rheumatoid arthritis drugs market size.

The primary factors fuelling the global rheumatoid arthritis drugs market growth include the rise in the prevalence of rheumatoid arthritis and the soaring geriatric population. Additionally, the transition from the management of symptoms to slowing the disease progression further steers the market augmentation. Although, side effects related to medication and higher cost of biosimilars and biologics impede the market growth. Conversely, rapid developments in the field of biologics and novel biosimilars are predicted to open lucrative opportunities for the proliferation of the market.


Key market players included in the global rheumatoid arthritis drugs industry are Abbvie, Biogen Inc., Bristol-Myers Squibb, Celgene Corp., Celltrion Inc., Johnson & Johnson, Medimmune LLC, Merck & Co. Inc., Novartis International AG, Takeda Pharmaceutical Co. Ltd.


Global Rheumatoid Arthritis Drugs Market Segmentation:

By Drug Class

  • Disease-Modifying Anti-Rheumatoid Drugs (DMARDs)
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Analgesics

By Route of Administration

  • Oral
  • Parental

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa


FutureWise Key Takeaways:

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth


Objectives of the Study:

  • To provide with an exhaustive analysis on the global rheumatoid arthritis drugs market by drug class, by route of administration and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, industry-specific restraints and opportunities)
  • To forecast and evaluate micro-markets and the overall market 
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa
  • To record, evaluate and analyse competitive landscape mapping- technological advancements, product launches, expansions and mergers


Get unlimited analyst support and customise this study further to your requirements, contact